A citation-based method for searching scientific literature

Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S W Tan. J Clin Oncol 2018
Times Cited: 117



Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C Heng, Suzanne E Dahlberg, Pasi A Jänne, Suman Verma, James Christensen, Peter S Hammerman, Lynette M Sholl. J Clin Oncol 2016
Times Cited: 312




List of shared articles



Times cited

Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.
Takashi Seto, Kadoaki Ohashi, Shunichi Sugawara, Makoto Nishio, Masayuki Takeda, Keisuke Aoe, Sanae Moizumi, Satoshi Nomura, Takeshi Tajima, Toyoaki Hida. Cancer Sci 2021
2

Crizotinib in Patients With MET-Amplified NSCLC.
D Ross Camidge, Gregory A Otterson, Jeffrey W Clark, Sai-Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I Shapiro, Mark A Socinski, Danielle A Murphy, Umberto Conte,[...]. J Thorac Oncol 2021
2

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib.
Aaron C Tan, Tracy J Loh, Xue Lin Kwang, Gek San Tan, Kiat Hon Lim, Daniel S W Tan. Lung Cancer (Auckl) 2021
0

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.
Matthew Lee, Prantesh Jain, Feng Wang, Patrick C Ma, Alain Borczuk, Balazs Halmos. Expert Opin Ther Targets 2021
0


HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence.
Jianjiang Fu, Xiaorui Su, Zhihua Li, Ling Deng, Xiawei Liu, Xuancheng Feng, Juan Peng. Oncogene 2021
1



Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
Carlo Genova, Giovanni Rossi, Marco Tagliamento, Erika Rijavec, Federica Biello, Luigi Cerbone, Lodovica Zullo, Francesco Grossi. Expert Rev Respir Med 2020
8

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Gonzalo Recondo, Magda Bahcall, Liam F Spurr, Jianwei Che, Biagio Ricciuti, Giulia C Leonardi, Ying-Chun Lo, Yvonne Y Li, Giuseppe Lamberti, Tom Nguyen,[...]. Clin Cancer Res 2020
41

Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward.
Umberto Malapelle, Lucia Anna Muscarella, Pasquale Pisapia, Antonio Rossi. Expert Opin Investig Drugs 2020
5

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.
M Schuler, R Berardi, W-T Lim, M de Jonge, T M Bauer, A Azaro, M Gottfried, J-Y Han, D H Lee, M Wollner,[...]. Ann Oncol 2020
26

Progress on treatment of MET signaling pathway in non-small cell lung cancer.
Xiaoqing Yu, Sizhe Yu, Yun Fan. Int J Clin Oncol 2020
1


MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Robin Guo, Jia Luo, Jason Chang, Natasha Rekhtman, Maria Arcila, Alexander Drilon. Nat Rev Clin Oncol 2020
27

Targeting MET Dysregulation in Cancer.
Gonzalo Recondo, Jianwei Che, Pasi A Jänne, Mark M Awad. Cancer Discov 2020
19

Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date.
Olivier Bylicki, Nicolas Paleiron, Jean-Baptiste Assié, Christos Chouaïd. Onco Targets Ther 2020
8

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Toshio Fujino, Kenichi Suda, Tetsuya Mitsudomi. Expert Opin Emerg Drugs 2020
3

Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
Ulrike Glaenzel, Yi Jin, Regine Hansen, Kirsten Schroer, Gholamreza Rahmanzadeh, Ulrike Pfaar, Jan Jaap van Lier, Hubert Borell, Axel Meissner, Gian Camenisch,[...]. Drug Metab Dispos 2020
2

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
114

The METeoric rise of MET in lung cancer.
Alex Friedlaender, Alexander Drilon, Giuseppe Luigi Banna, Solange Peters, Alfredo Addeo. Cancer 2020
7

MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study.
Xue-Wen Liu, Xin-Ru Chen, Yu-Ming Rong, Ning Lyu, Chun-Wei Xu, Fang Wang, Wen-Yong Sun, San-Gao Fang, Jing-Ping Yuan, Hui-Juan Wang,[...]. Transl Oncol 2020
3


Update on emerging biomarkers in lung cancer.
Eric H Bernicker, Timothy Craig Allen, Phillip T Cagle. J Thorac Dis 2019
12